Cristina Chang: The Importance of The New ET Treatments
Cristina Chang, Chief Medical Officer (CMO), Global at Harvest Integrated Research Organization (HiRO), shared a post on LinkedIn:
“What is essential thrombocythemia – and why are new treatments important?
Essential thrombocythemia (ET) is a rare, chronic myeloproliferative neoplasm in which the bone marrow produces too many platelets.
Despite the high platelet count, patients face the seemingly contradictory risks of both dangerous blood clots and abnormal bleeding.
ET is commonly driven by mutations in JAK2, CALR, or MPL.
Patients may experience fatigue, headaches, dizziness, visual disturbances, night sweats, an enlarged spleen, or painful redness and burning in the hands and feet.
More serious complications include stroke, heart attack, deep-vein thrombosis, pulmonary embolism, and gastrointestinal bleeding.
Treatment is guided by age, mutation status, cardiovascular risk factors, and previous thrombosis.
It may include observation, low-dose aspirin, and cytoreductive therapy to control blood counts and reduce complications.
Because ET is a lifelong disease with a small risk of progression to myelofibrosis or acute myeloid leukemia, patients require long-term monitoring – and treatments that can address not only platelet counts but also the underlying disease biology.”
Stay updated with Hemostasis Today.
-
Oct 19, 2026, 08:20Cory Dugan: The IRONWOMAN Trial Individual Responses to IV Iron Therapy in Active Women
-
Oct 19, 2026, 07:36Johannes Kaesmacher: Cerebral No-Reflow After Thrombectomy Toward a Standardized Definition
-
Oct 19, 2026, 07:33Beth Psaila: Highlights from IACH Annual Meeting and MPN Horizons
-
Oct 19, 2026, 07:29Wolfgang Miesbach: Can Losartan Activate Brown Fat? – Nature Study Explores New Therapeutic Link
-
Oct 19, 2026, 07:22Ruben Mesa: Honored to Speak at the Tandem MPN Meetings of IACH
-
Oct 19, 2026, 07:19Saneha Anjum Shaikh: Parul University Partners with Raktasevak Bike Ride 2026 for Blood Donation Drive
-
Oct 19, 2026, 07:09Alejandro González Veliz: No ST Elevation Does Not Guarantee an Open Coronary Artery
-
Oct 19, 2026, 06:02Thomas Dayspring: Vascular Resilience – What Is It and How Can We Measure It?
-
Oct 19, 2026, 05:53Kevon Dindial: Collaboration for Better Childhood Cancer OutcomesÂ